Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies
This study has been completed.
Sponsor:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00004851
First Posted: December 10, 2002
Last Update Posted: March 4, 2008
Information provided by:
National Institutes of Health Clinical Center (CC)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To generate a library of genes that reflect the entirety of antibody responses to hepatitis C virus (HCV) made during the 20-year course of HCV infection in a single patient (WH) whose viral quasispecies has been extensively characterized. In addition to characterizing the sequential events in antibody formation and their relationship to the changing pattern of viral quasispecies, we hope to identify neutralizing antibodies and the epitopes to which they are directed. Ultimately we seek to gain insight into the host mechanisms that suppress viral replication and to translate this to therapeutic and preventive modalities.
| Condition |
|---|
| Hepatitis C |
| Study Type: | Observational |
| Official Title: | Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies |
Resource links provided by NLM:
Further study details as provided by National Institutes of Health Clinical Center (CC):
| Estimated Enrollment: | 1 |
| Study Start Date: | April 1999 |
| Estimated Study Completion Date: | May 2001 |
To generate a library of genes that reflect the entirety of antibody responses to hepatitis C virus (HCV) made during the 20-year course of HCV infection in a single patient (WH) whose viral quasispecies has been extensively characterized. In addition to characterizing the sequential events in antibody formation and their relationship to the changing pattern of viral quasispecies, we hope to identify neutralizing antibodies and the epitopes to which they are directed. Ultimately we seek to gain insight into the host mechanisms that suppress viral replication and to translate this to therapeutic and preventive modalities.
Eligibility
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Persistent infection with mild hepatitis that is non-progressive.
Contacts and Locations
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004851
Locations
| United States, Maryland | |
| Warren G. Magnuson Clinical Center (CC) | |
| Bethesda, Maryland, United States, 20892 | |
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00004851 History of Changes |
| Other Study ID Numbers: |
990090 99-CC-0090 |
| First Submitted: | March 2, 2000 |
| First Posted: | December 10, 2002 |
| Last Update Posted: | March 4, 2008 |
| Last Verified: | March 2000 |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
HCV Antibody Library |
Additional relevant MeSH terms:
|
Hepatitis C Hepatitis, Viral, Human Virus Diseases Flaviviridae Infections RNA Virus Infections Hepatitis Liver Diseases |
Digestive System Diseases Antibodies Immunoglobulins Hepatitis C Antibodies Immunologic Factors Physiological Effects of Drugs |